chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Narrative: Patient reported runny nose, tearing, and mild difficulty swallowing, cough, and tightness in throat within 1 minute after administration of Pfizer covid vaccine. Abated over about 15 minutes. Patient was observed for 30 minutes by which point these adverse effects had completely resolved. Patient did not require any intervention.
Typhoid injection given, hot laid down, knees up.  Hep A given became completely unresponsive staring, shallow respiratory rate, irregular pulse.  3:05: Epi 0.5cc given SC B/P 151/80.  3:10: O2 2iL via nasal cannal EMS called 3:13 MD arrived B/P: 170/100, 3:16: 130/80, 3:15: 170/100, respiratory shallow some response to steroid rub 3:20 seizure like activity, body jerked <1min.  3:26: to hospital per EMS. 5:00 okay, sent home.  01/28/04: working fine, no problems.
expired Moderna vaccine administered to patients; Date the vial was expired on 01-APR-2022 and initially stored in the refrigerator: 05-APR-2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired Moderna vaccine administered to patients) and PRODUCT STORAGE ERROR (Date the vial was expired on 01-APR-2022 and initially stored in the refrigerator: 05-APR-2022) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired Moderna vaccine administered to patients) and PRODUCT STORAGE ERROR (Date the vial was expired on 01-APR-2022 and initially stored in the refrigerator: 05-APR-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (expired Moderna vaccine administered to patients) and PRODUCT STORAGE ERROR (Date the vial was expired on 01-APR-2022 and initially stored in the refrigerator: 05-APR-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant drug information was provided.  No of dose vials used 20 doses.  Patients were received Moderna COVID-19 vaccine vials with a manufacturing date of 1Dec2021 and an expiration date of 1Apr2022 (Lot: 026L21B). Also received Moderna vaccine vials with a manufacturing date of 10Dec2021 with an expiration date of JUL2022 (Lot: 001M21A). It was reported that the administration of vaccine occurred from 6-Apr-2022 to 9-Apr-2022. Patients not had adverse reaction after the vaccination. The manufacturing date of the vial was 1-Dec-2021 Vial was initially placed in refrigerator on 5-Apr-2022. The product didn't undergo any temperature excursion issue. Reporter wants to know if the patients need to be re-vaccinated. No treatment drug information was reported.   This case was linked to MOD-2022-538688, MOD-2022-538614, MOD-2022-537580, MOD-2022-538672, MOD-2022-538673, MOD-2022-538675, MOD-2022-538675, MOD-2022-538677, MOD-2022-538678, MOD-2022-538681, MOD-2022-538682, MOD-2022-538688, MOD-2022-538689, MOD-2022-538691, MOD-2022-538692, MOD-2022-538693, MOD-2022-538696, MOD-2022-538697, MOD-2022-538701, MOD-2022-538702, MOD-2022-538689, MOD-2022-538672, MOD-2022-538676 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 11-Apr-2022: Patient Identifier added.
Pfizer vaccine for her second dose in right deltoid; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Pfizer vaccine for her second dose in right deltoid) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024C21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 02-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Pfizer vaccine for her second dose in right deltoid). On 02-Jun-2021, INTERCHANGE OF VACCINE PRODUCTS (Pfizer vaccine for her second dose in right deltoid) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported by the reporter. The treatment information was unknown.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Follow up received 29-JUL-2021. Added reporter's comment no AE experienced as a result of the event to the narrative.
Severe chills; joint pain; This is a spontaneous report from a contactable other healthcare professional (patient). A 60-year-old female patient received bnt162b2, via an unspecified route of administration on 30Jan2021 at 04:45, single dose in the Left arm for covid-19 immunization. Medical history included Hashimotos Thyroiditis. Concomitant medication included thyroid (ARMOUR THYROID). The patient previously took Levoquine and experienced allergies. The patient was not pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. In Feb2021, the patient experienced severe chills and joint pain still 4 days later. The patient did not receive treatment for the adverse events. The outcome of the events was recovering.   Information on the lot/batch number has been requested.
Fever to 100.5 F, three vesicular lesions noted (one on arm, one on head, one on back). On 1/27/2010 a few lesions scattered to chest and back. Mother states child was not exposed to varicella.
This spontaneous report as received from a pharmacist refers to a newborn female patient of unknown age. On 20-OCT-2012 22:12, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not reported. Two lot# were involved and the lot# were reported as: 0294AE, expiry date on 06-SEP-2014; and 0385AE, expiry date on 08-NOV-2014. It was unspecified which lot# the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
2 mo old male received vaccines 4/10/09.  2hrs after vaccine started develop rash to body, which spread the following day with swelling.  Seen in ER that day of increase spread of rash + given shot which decrease rash, given Benadryl + Prednisone.
Really itchy rash in the upper arm and legs.; This spontaneous case was reported by a physician assistant (subsequently medically confirmed) and describes the occurrence of RASH PRURITIC (Really itchy rash in the upper arm and legs.) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     No Medical History information was reported.  On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 09-Feb-2021, the patient experienced RASH PRURITIC (Really itchy rash in the upper arm and legs.).   At the time of the report, RASH PRURITIC (Really itchy rash in the upper arm and legs.) outcome was unknown. Not Provided    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of this event, a causal relationship cannot be excluded.
Patient was given Moderna vaccine in clinic. After the injection when entering information into our computer charting system I realized the Moderna had expired on 9/10/2022.  I notified BSN, RN the Director of Nursing she stated to the the manufacturer. Moderna was informed of the incident and we were instructed to check with our Medical Director. Nurse spoke with the medical director Dr. and the Health Commissioner and were in agreeance the the dose did not to be repeated based on information from Moderna.  Attempted so far to call the client and notify of incident but phone is not in service. Will continue to reach out.
Treatment ATG horse serum for 4 days in hospital in September 99. GCSF shots daily since Sept. 99 and continuing. 11 shots for SCF (clinical trial injections) in September/October 1999. DX with severe aplastic anemia in June 1999. Post first vax, patient experienced reduced appetite which continued throughout the school year. At the end of January 1999, he began having difficulty sleeping. June 24, 1999 patient was evaluated for pancytopenia. He had multiple bruises on lower extremities and petechial rash, looked slightly pale. He had upper respiratory infection symptoms and mild coughing one week prior to evaluation. Evidence of Parvovirus infection in the past. Increased MCV suggested that bone marrow condition had been going on for sometime.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On an unknown date the patient was vaccinated with VAQTA lot number reported as M005274 and expiration date of 03-APR-2018 for prophylaxis. On an unknown date was reported incorrect product storage and no adverse event. The outcome of incorrect product storage and no adverse event is unknown. The reporter considered incorrect product storage and no adverse event to be not related to VAQTA. This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1708USA001111:  US-009507513-1708USA000453:
Td given 30AUG93 lt deltoid; seen 2SEP93 for PPD reading & 7cm reddness noted @ Td site; related h/a, myalgia, flu like sxs; 30AUGPM 1SEP Pm which have resolved; has 7Cm reddness w/4cm firm central induration  deep red & warm to touch;
Pain in the left arm and swelling under the armpits and a lot of pain in the entire left arm as well as in the armpits only in the left part.
Pt. states that after receiving the 3rd dose of Phizer 12/15/2021, started experiencing symptoms that evening of chills, fatigue, soreness at the injection site, and loss of appetite. No noted Primary visit/communications.
Possible allergic reaction to vaccines he received in left arm 3 days ago. The area is red, hot and firm to touch. No fever reported. Prescribed cephalexin 500 mg capsule.
chills; fever of 102 degrees; received his first dose of Shingrix vaccine 4 weeks ago; This case was reported by a consumer via call center representative and described the occurrence of chills in a 60-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of chills (received 1st dose 4 weeks ago in the left arm intramuscularly, refer case US2020AMR225455). Concurrent medical conditions included type ii diabetes mellitus.   On 10th November 2020, the patient received the 2nd dose of Shingrix (intramuscular). On 10th November 2020, less than a day after receiving Shingrix, the patient experienced chills, fever and drug dose administration interval too short. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the chills and fever were not recovered/not resolved and the outcome of the drug dose administration interval too short was unknown.   It was unknown if the reporter considered the chills and fever to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix in the left arm and had fever of 102 degrees F and chills.  The patient reported the fever has gone down but still had chills currently. The patient did not had lot number or expiration date information to provide.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR225455:same reporter.
'Covid Arm' reaction to Moderna COVID-19 Vaccine EUA at injection site. Fine the first day, second - third day slight swelling, redness and a little sore. This went away by the 3rd day.  Day 7 post injection  in the evening noticed slight redness and itch. Day 8 have 2 inch diameter red area around injection site, arm itchy and area swollen, warm to the touch with hard lump in the middle. Took benedryl and iced all day and night.  Day 9 -Still red, itchy, swollen and warm but lump gone. Can't take benedryl and function so just icing. Hopefully will go away soon.
Right after injection, both sites became red and warm and sore (5/31), gave tylenol, (6/2) severe muscle aches and back pain. Symptoms resolve by June 6, the site of shingles shot (R deltoid) still warm
Information has been received from a registered nurse concerning a male who was vaccinated with a dose of Vaqta (previously reported as MMRV (Oka/Merck upgrade process)). Subsequently the patient experienced severe leg pain. The patient's outcome was recovered. Unspecified medical attention was sought. There was no product quality complaint involved. Additional information has been requested.
Itching began on L arm 7 days post injection, on day 8 noticed a 6 inch diameter bulls-eye rash centered around injection site. Within a few hours, face began to flush and feel hot and itchy.  Saw a NP who ruled out cellulitis and recommended Benadryl.  Took 2 Benadryl tablets by noon on day 8 and almost immediately noticed facial itching/"hot" sensation improving. Within 2-3 hours, rash began to fade in color. Continued taking Benadryl as directed on box and by the end of day 9 rash had almost faded to nothing with no residual symptoms remaining.
Pt. stated she felt flush. Vitals were taken pt. observed in recumbent position, water given.  Pt. condition improved and she went home.
Case number PHEH2014US025131, is an initial spontaneous report from a nurse received on 09 Dec 2014. This report refers to a 62-year-old female patient. Historical conditions were reported. No concomitant medication was reported. The patient was vaccinated with FLUVIRIN (batch number: 145701) intramuscularly at a dose of 0.5 ml on 21 Oct 2014. The nurse reported that FLUVIRIN administered had 12 separate temperature excursions lasting for 30 minutes over a period of 34 days. The temperatures excursion began on 16 Oct 2014 and the temperature was between 46 to 49 degree F during the excursion. No adverse event was reported following this maladministration.
Pharmacist reports interruption of schedule pertaining to GARDASIL 9. Pharmacist reports that Patient received GARDASIL 9 at the age of 11 and is now 16 and requesting to finish series.; No additional AEs reported. No PQCs reported. No further details provided.; This spontaneous report has been received from a registered pharmacist concerning a currently 16-year-old patient of unknown gender. The patient's concomitant therapies, pertinent medical history, and drug reactions/allergies were not reported.  In approximately 2017 (at the age of 11 years old), the patient received HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection (strength, dose, route of administration, lot#, and expiration date were not provided) for prophylaxis.  On an unspecified date in July 2022 (reported as "now 16 years old"), the patient was requesting to finish series, which indicated an interruption of schedule (inappropriate schedule of product administration). The report stated that the patient did not receive first dose at his facility and refused to provide any additional information at this time. There was no additional adverse event (AE) reported.
Suspected Vaccination Failure; All my friends who got that vaccine got the shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in an unknown number of patients who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The reporter stated that all his/her friends who got that vaccine got the shingles. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and as details regarding laboratory confirmation of shingles was not provided.
Case number PHEH2015US026846, is a spontaneous report initially received from a nurse on 22 Dec 2015. This report refers to a 61 years old female patient. Past medical history and concomitant medications were not reported. The patient was vaccinated with FLUVIRIN (batch number: 1514501, expiry date: May 2016) into left deltoid on 07 Oct 2015 which was out of temperature range (34 degrees Celsius). The reporter stated that she did not know why the refrigerator was out of temperature range for an unspecified amount of time overnight. She checked the temperature before she left for the day and when she arrived the next day and the temperature was fine. It was a new refrigerator and there were not problems since the temperature excursion. No adverse even was reported following this medication error (incorrect storage of drug). Follow up information received via nurse on 26 Jan 2016: Reporter's comments updated.
Received the Moderna COVID-19 vaccine recently had COVID; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (Received the Moderna COVID-19 vaccine recently had COVID) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Received the Moderna COVID-19 vaccine recently had COVID). At the time of the report, COVID-19 (Received the Moderna COVID-19 vaccine recently had COVID) outcome was unknown.            Concomitant medications were not reported. Reporter stated that the patient might have received the Pfizer or Moderna COVID-19 vaccine recently had COVID. No treatment information was provided by the reporter.   Reporter did not allow further contact
Patient describes that she had a sore arm the night of. The next day she reported feeling "super super tired" with sore arm, chills, and her eyes were hurting. When asked to describe the pain, she said she just felt like her eyes were tired and hurt. Couldn't describe eye pain well. Recommended that patient follow up with a doctor about eye pain especially if it gets worse/does not go away.
Said shot should have been given subq and not IM. She also had swelling and redness at the injection site.
Redness around injection site, pain upon press the site. Swelling and hot when touched.
sick as a dog; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick as a dog) in a 35-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (sick as a dog). At the time of the report, ILLNESS (sick as a dog) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       Concomitant medication information was not provided. Treatment information was not provided.
Severe chills, headache, body ache, dizziness. Low fever. Almost passed out.
28 patient received expired vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (28 patient received expired vaccine) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009C21A) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: PFIZER BIONTECH COVID-19 VACCINE (First dose) on 15-May-2021 and PFIZER BIONTECH COVID-19 VACCINE (Second dose) on 05-Jun-2021. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.    On 10-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (28 patient received expired vaccine). On 10-Dec-2021, EXPIRED PRODUCT ADMINISTERED (28 patient received expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported   No treatment information was provided
1:30 pm Mother noted swelling around eyes. 2:00 pm eyes shut swelling continued; 2:15 pm facial swelling went to ER for treatment. Treatment in ER - Cortisone and Benadryl by mouth administered. Prescription for cortisone to give one daily for 2-3 days Benadryl as needed.
A report has been received from a Health Professional concerning an 9 year old, female subject, who had been receiving Nasal FLUMIST Quadrivalent, 0.2 milliliters. FLUMIST Quadrivalent started on 27-OCT-2015. On 28-OCT-2015 the patient tested positive for the flu, less than 24 hours after receiving FLUMIST. The outcome of the event of positive test for flu is unknown. The report was considered to be non-serious by the company physician.
One day after vaccine-lethargy, no energy Two days after vaccine- lethargy, no energy, joint pain in arms and hands, swollen face  Three days after-same symptoms  Four days after-same symptoms but lethargy worse and some dizziness
inject was given 27APR94, & half dollar size reddened & sore area noted'
Left leg "killing patient"; Hurting at the back of left leg; Felt like a pulled muscle on left leg; Diagnosed with Shingles; Raised rash on back of left leg; Tiny bruise at injection site; A spontaneous report was received from a consumer concerning a 62 Years old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events includes Developed a tiny bruise at site of injection, Patient noticed left leg was killing patient, hurting in back of leg, felt like a pulled muscle, noticed raised rash on back of left leg, Went to Urgent Care and diagnosed with Shingles  The patient's medical history was not provided. Concomitant medications used by the patient were not provided. On 30 JAN 2021, prior to the onset of the events the patient received one of two planned doses of mRNA-1273 (Batch Number Unknown) via unspecified route on her Right arm for prophylaxis of COVID-19 infection.  Treatment was done for Shingles with Valtrex. Action taken with mRNA-1273 in response to the events was not provided.  The outcome of the events was unknown and for rash it is said to be Resolving.  Patient given consent to follow-up with her